| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 27 | 2024 | 426 | 10.160 |
Why?
|
| Kidney Neoplasms | 32 | 2024 | 621 | 10.060 |
Why?
|
| Biomarkers, Tumor | 27 | 2022 | 1464 | 4.820 |
Why?
|
| Prostatic Neoplasms | 44 | 2023 | 1721 | 3.750 |
Why?
|
| Mutation | 14 | 2021 | 3968 | 2.060 |
Why?
|
| Immunohistochemistry | 21 | 2022 | 1753 | 1.970 |
Why?
|
| Magnetic Resonance Imaging | 33 | 2023 | 3362 | 1.780 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2022 | 182 | 1.760 |
Why?
|
| Neurofibromin 2 | 3 | 2022 | 30 | 1.750 |
Why?
|
| Thyroid Neoplasms | 9 | 2022 | 408 | 1.640 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2018 | 383 | 1.470 |
Why?
|
| Male | 100 | 2023 | 40965 | 1.440 |
Why?
|
| Aged | 71 | 2021 | 18415 | 1.380 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 17 | 2023 | 294 | 1.370 |
Why?
|
| Stromal Cells | 3 | 2019 | 143 | 1.360 |
Why?
|
| Middle Aged | 74 | 2021 | 25028 | 1.310 |
Why?
|
| Prostate | 16 | 2023 | 378 | 1.300 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2019 | 80 | 1.230 |
Why?
|
| Leiomyoma | 2 | 2022 | 191 | 1.220 |
Why?
|
| Humans | 119 | 2024 | 86643 | 1.200 |
Why?
|
| Sarcoma | 3 | 2019 | 215 | 1.190 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 5 | 2023 | 54 | 1.110 |
Why?
|
| Translocation, Genetic | 4 | 2023 | 265 | 1.100 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 1056 | 1.090 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 61 | 1.040 |
Why?
|
| Meningioma | 2 | 2022 | 60 | 1.030 |
Why?
|
| Nephrectomy | 6 | 2020 | 294 | 1.020 |
Why?
|
| Thyroid Nodule | 3 | 2022 | 51 | 1.020 |
Why?
|
| Carcinoma, Transitional Cell | 6 | 2019 | 164 | 1.020 |
Why?
|
| Prostatectomy | 18 | 2021 | 471 | 0.970 |
Why?
|
| Cysts | 2 | 2023 | 104 | 0.960 |
Why?
|
| Pancreatic Neoplasms | 5 | 2018 | 645 | 0.950 |
Why?
|
| Biopsy, Fine-Needle | 11 | 2022 | 93 | 0.930 |
Why?
|
| Submandibular Gland Neoplasms | 2 | 2021 | 7 | 0.910 |
Why?
|
| Adult | 50 | 2021 | 25648 | 0.910 |
Why?
|
| Transcription Factors | 4 | 2021 | 1565 | 0.890 |
Why?
|
| Biopsy | 12 | 2020 | 1163 | 0.890 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2014 | 15 | 0.860 |
Why?
|
| Contrast Media | 17 | 2023 | 1078 | 0.850 |
Why?
|
| Retrospective Studies | 34 | 2023 | 8489 | 0.850 |
Why?
|
| Epithelium | 3 | 2015 | 319 | 0.840 |
Why?
|
| Chromosomes, Human, X | 2 | 2023 | 55 | 0.830 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2018 | 16 | 0.820 |
Why?
|
| Eosinophilia | 2 | 2020 | 84 | 0.810 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 736 | 0.800 |
Why?
|
| Female | 50 | 2022 | 44532 | 0.800 |
Why?
|
| GATA3 Transcription Factor | 3 | 2018 | 48 | 0.790 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 63 | 0.780 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 128 | 0.760 |
Why?
|
| Adenocarcinoma | 6 | 2019 | 1169 | 0.750 |
Why?
|
| Carcinoma, Papillary | 6 | 2018 | 158 | 0.730 |
Why?
|
| Lymphatic Metastasis | 5 | 2018 | 486 | 0.720 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 348 | 0.710 |
Why?
|
| Kidney | 4 | 2024 | 1241 | 0.710 |
Why?
|
| Abdominal Wall | 1 | 2019 | 30 | 0.710 |
Why?
|
| Eosinophils | 1 | 2020 | 194 | 0.710 |
Why?
|
| Seminal Vesicles | 3 | 2016 | 39 | 0.710 |
Why?
|
| Adenocarcinoma, Follicular | 3 | 2017 | 51 | 0.710 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 40 | 0.700 |
Why?
|
| Carcinoma | 3 | 2024 | 436 | 0.700 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 19 | 0.700 |
Why?
|
| Phenotype | 8 | 2021 | 2378 | 0.690 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 279 | 0.690 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 17 | 0.680 |
Why?
|
| DNA Helicases | 1 | 2019 | 79 | 0.670 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 79 | 0.660 |
Why?
|
| Phyllodes Tumor | 1 | 2018 | 7 | 0.660 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 696 | 0.640 |
Why?
|
| Amyloidosis | 1 | 2019 | 115 | 0.640 |
Why?
|
| Cytodiagnosis | 3 | 2019 | 42 | 0.630 |
Why?
|
| Melanins | 1 | 2017 | 23 | 0.630 |
Why?
|
| Lymph Node Excision | 2 | 2016 | 217 | 0.630 |
Why?
|
| Aged, 80 and over | 24 | 2019 | 6509 | 0.630 |
Why?
|
| Cystadenoma | 2 | 2016 | 19 | 0.630 |
Why?
|
| Gene Fusion | 1 | 2017 | 38 | 0.620 |
Why?
|
| MicroRNAs | 1 | 2022 | 534 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1197 | 0.620 |
Why?
|
| Atrial Septum | 1 | 2017 | 9 | 0.610 |
Why?
|
| Lipomatosis | 1 | 2017 | 9 | 0.610 |
Why?
|
| Hamartoma | 1 | 2017 | 31 | 0.600 |
Why?
|
| Flow Cytometry | 1 | 2019 | 679 | 0.590 |
Why?
|
| Epithelioid Cells | 1 | 2016 | 13 | 0.580 |
Why?
|
| Neoplasm Grading | 11 | 2021 | 357 | 0.580 |
Why?
|
| Mullerian Ducts | 1 | 2016 | 17 | 0.570 |
Why?
|
| Monosomy | 1 | 2016 | 12 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 85 | 0.550 |
Why?
|
| Lymph Nodes | 3 | 2016 | 533 | 0.550 |
Why?
|
| Bile Duct Neoplasms | 2 | 2014 | 79 | 0.540 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 144 | 0.530 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 1673 | 0.530 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 140 | 0.530 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.530 |
Why?
|
| Parotid Neoplasms | 2 | 2021 | 17 | 0.520 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2020 | 28 | 0.520 |
Why?
|
| Diagnosis, Differential | 12 | 2021 | 1565 | 0.510 |
Why?
|
| Prostatic Hyperplasia | 4 | 2019 | 88 | 0.500 |
Why?
|
| Epithelial Cells | 2 | 2018 | 669 | 0.500 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 15 | 0.490 |
Why?
|
| Insulin | 1 | 2019 | 1160 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 1313 | 0.490 |
Why?
|
| Fatal Outcome | 4 | 2019 | 293 | 0.480 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 1939 | 0.470 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1458 | 0.470 |
Why?
|
| Image Enhancement | 7 | 2018 | 563 | 0.470 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 108 | 0.460 |
Why?
|
| Adenoma | 3 | 2024 | 235 | 0.460 |
Why?
|
| Urinalysis | 1 | 2013 | 33 | 0.450 |
Why?
|
| Frozen Sections | 1 | 2013 | 48 | 0.440 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 166 | 0.440 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 51 | 0.440 |
Why?
|
| Testis | 2 | 2018 | 152 | 0.430 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 456 | 0.430 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 325 | 0.430 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 1208 | 0.420 |
Why?
|
| Cryptorchidism | 1 | 2011 | 11 | 0.420 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 526 | 0.400 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 2271 | 0.400 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 2262 | 0.400 |
Why?
|
| Ascitic Fluid | 1 | 2010 | 37 | 0.390 |
Why?
|
| Pleural Effusion | 1 | 2010 | 45 | 0.390 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2010 | 9 | 0.370 |
Why?
|
| Prognosis | 10 | 2021 | 3679 | 0.370 |
Why?
|
| Gadolinium DTPA | 7 | 2015 | 261 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1373 | 0.360 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 46 | 0.360 |
Why?
|
| Reproducibility of Results | 12 | 2021 | 2705 | 0.360 |
Why?
|
| Neoplasms, Second Primary | 2 | 2010 | 252 | 0.360 |
Why?
|
| Young Adult | 10 | 2020 | 5976 | 0.350 |
Why?
|
| Adolescent | 9 | 2020 | 8981 | 0.350 |
Why?
|
| Prostate-Specific Antigen | 3 | 2018 | 353 | 0.350 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 469 | 0.340 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 1991 | 0.340 |
Why?
|
| Myoepithelioma | 1 | 2008 | 11 | 0.330 |
Why?
|
| Angiomyolipoma | 2 | 2021 | 15 | 0.320 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7993 | 0.310 |
Why?
|
| Metaplasia | 2 | 2018 | 37 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2022 | 1204 | 0.300 |
Why?
|
| Tissue Array Analysis | 4 | 2017 | 124 | 0.300 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2015 | 663 | 0.290 |
Why?
|
| Urologic Neoplasms | 2 | 2019 | 77 | 0.290 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 105 | 0.290 |
Why?
|
| Keratin-7 | 3 | 2020 | 10 | 0.280 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2006 | 1 | 0.280 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2005 | 1 | 0.280 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 20 | 0.270 |
Why?
|
| Thyroid Gland | 3 | 2019 | 270 | 0.270 |
Why?
|
| Liver | 2 | 2021 | 1230 | 0.250 |
Why?
|
| Thyroidectomy | 3 | 2017 | 170 | 0.240 |
Why?
|
| ROC Curve | 8 | 2021 | 752 | 0.240 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 138 | 0.240 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 144 | 0.240 |
Why?
|
| Mediator Complex | 1 | 2023 | 12 | 0.230 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2021 | 25 | 0.230 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2022 | 10 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2023 | 63 | 0.210 |
Why?
|
| Ultrasonography | 3 | 2019 | 695 | 0.210 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2022 | 66 | 0.200 |
Why?
|
| Submandibular Gland | 1 | 2021 | 16 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2015 | 332 | 0.200 |
Why?
|
| Keratin-20 | 1 | 2020 | 6 | 0.200 |
Why?
|
| Parotid Gland | 1 | 2021 | 31 | 0.200 |
Why?
|
| Vimentin | 1 | 2020 | 44 | 0.190 |
Why?
|
| Clathrin Heavy Chains | 1 | 2020 | 4 | 0.190 |
Why?
|
| Placenta | 1 | 2022 | 175 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2021 | 4213 | 0.190 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2020 | 9 | 0.190 |
Why?
|
| Radiology | 1 | 2023 | 194 | 0.190 |
Why?
|
| Stomach Neoplasms | 2 | 2015 | 266 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 353 | 0.180 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 117 | 0.180 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 167 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 552 | 0.180 |
Why?
|
| beta Catenin | 2 | 2018 | 251 | 0.180 |
Why?
|
| Contractile Proteins | 1 | 2019 | 54 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 102 | 0.170 |
Why?
|
| Dermatofibrosarcoma | 1 | 2019 | 13 | 0.170 |
Why?
|
| Specimen Handling | 2 | 2022 | 98 | 0.170 |
Why?
|
| Transcriptome | 2 | 2021 | 580 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 250 | 0.170 |
Why?
|
| Vena Cava, Superior | 1 | 2019 | 59 | 0.170 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 71 | 0.170 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 64 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3640 | 0.170 |
Why?
|
| Silicon Dioxide | 1 | 2018 | 39 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 179 | 0.160 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 384 | 0.160 |
Why?
|
| Kallikreins | 1 | 2018 | 47 | 0.160 |
Why?
|
| Gadolinium | 1 | 2018 | 103 | 0.160 |
Why?
|
| Chicago | 2 | 2020 | 1379 | 0.160 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2018 | 40 | 0.160 |
Why?
|
| PAX8 Transcription Factor | 1 | 2017 | 23 | 0.160 |
Why?
|
| Keratins | 1 | 2017 | 63 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2017 | 8 | 0.150 |
Why?
|
| Observer Variation | 5 | 2021 | 602 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 99 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 107 | 0.150 |
Why?
|
| Hypertrophy | 1 | 2017 | 62 | 0.150 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2017 | 18 | 0.150 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2017 | 43 | 0.150 |
Why?
|
| Feasibility Studies | 4 | 2021 | 751 | 0.150 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 13 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 123 | 0.150 |
Why?
|
| Multimodal Imaging | 2 | 2018 | 110 | 0.150 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2016 | 44 | 0.150 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2903 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 429 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.150 |
Why?
|
| Cystadenocarcinoma | 1 | 2016 | 12 | 0.140 |
Why?
|
| Genomics | 1 | 2022 | 720 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 1384 | 0.140 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 158 | 0.140 |
Why?
|
| Symptom Assessment | 1 | 2016 | 65 | 0.140 |
Why?
|
| Urinary Bladder | 2 | 2018 | 246 | 0.140 |
Why?
|
| Urothelium | 1 | 2016 | 70 | 0.140 |
Why?
|
| Carcinoma, Ductal | 2 | 2016 | 18 | 0.130 |
Why?
|
| Algorithms | 2 | 2014 | 1830 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2016 | 329 | 0.130 |
Why?
|
| Quality of Life | 2 | 2021 | 1585 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 128 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 193 | 0.130 |
Why?
|
| Splenectomy | 1 | 2014 | 82 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 556 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 5 | 0.130 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 11 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 418 | 0.130 |
Why?
|
| Quinazolines | 1 | 2016 | 220 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 223 | 0.120 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2014 | 3 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 559 | 0.120 |
Why?
|
| Anatomic Landmarks | 1 | 2014 | 31 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 853 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 546 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 107 | 0.120 |
Why?
|
| Exome | 1 | 2014 | 127 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2014 | 148 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2013 | 30 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 286 | 0.110 |
Why?
|
| Parathyroid Glands | 1 | 2013 | 74 | 0.110 |
Why?
|
| Vascular Neoplasms | 1 | 2012 | 19 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2013 | 91 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 532 | 0.110 |
Why?
|
| Cadherins | 1 | 2013 | 151 | 0.110 |
Why?
|
| Microvessels | 1 | 2012 | 70 | 0.110 |
Why?
|
| DNA Repair | 1 | 2014 | 356 | 0.110 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 48 | 0.110 |
Why?
|
| Alcoholism | 1 | 2014 | 172 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 121 | 0.110 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2012 | 12 | 0.110 |
Why?
|
| Seminiferous Tubules | 1 | 2011 | 8 | 0.110 |
Why?
|
| Neprilysin | 1 | 2012 | 42 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 321 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 589 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2018 | 579 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 839 | 0.100 |
Why?
|
| Germ Cells | 1 | 2011 | 126 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2014 | 311 | 0.100 |
Why?
|
| Child | 2 | 2013 | 6927 | 0.100 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 8 | 0.090 |
Why?
|
| Thyroiditis | 1 | 2010 | 10 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2010 | 10 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 303 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 582 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 81 | 0.090 |
Why?
|
| Meglumine | 2 | 2021 | 39 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 763 | 0.090 |
Why?
|
| Neoplasms | 2 | 2022 | 2898 | 0.090 |
Why?
|
| Ploidies | 2 | 2020 | 40 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 136 | 0.080 |
Why?
|
| Organometallic Compounds | 2 | 2021 | 132 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 509 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 536 | 0.080 |
Why?
|
| Chromosome Aberrations | 2 | 2020 | 387 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 772 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 281 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 963 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 1531 | 0.070 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2005 | 5 | 0.070 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2005 | 31 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2018 | 289 | 0.070 |
Why?
|
| Infant | 1 | 2011 | 3046 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 74 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2019 | 2261 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2011 | 3612 | 0.060 |
Why?
|
| Pneumonia | 1 | 2005 | 179 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2015 | 334 | 0.060 |
Why?
|
| Radiography | 2 | 2015 | 813 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 579 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2022 | 40 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 78 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2022 | 52 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2022 | 18 | 0.050 |
Why?
|
| Motion | 1 | 2022 | 85 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2022 | 76 | 0.050 |
Why?
|
| Water | 1 | 2023 | 277 | 0.050 |
Why?
|
| Pathologists | 1 | 2021 | 24 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2012 | 3241 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 235 | 0.050 |
Why?
|
| Azure Stains | 1 | 2021 | 6 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2021 | 18 | 0.050 |
Why?
|
| Xanthenes | 1 | 2021 | 23 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 38 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 167 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2767 | 0.050 |
Why?
|
| Washington | 1 | 2020 | 48 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 150 | 0.050 |
Why?
|
| Adenomatous Polyps | 1 | 2019 | 11 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 207 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 502 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1851 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 171 | 0.040 |
Why?
|
| Pelvic Exenteration | 1 | 2019 | 5 | 0.040 |
Why?
|
| Microbubbles | 1 | 2019 | 36 | 0.040 |
Why?
|
| Emulsions | 1 | 2018 | 19 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 67 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
| Cystectomy | 1 | 2019 | 102 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 689 | 0.040 |
Why?
|
| Dogs | 1 | 2018 | 685 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 555 | 0.040 |
Why?
|
| Immunoassay | 1 | 2017 | 92 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 989 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 943 | 0.040 |
Why?
|
| ras Proteins | 1 | 2018 | 128 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 320 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 339 | 0.040 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 9 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 814 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 5417 | 0.040 |
Why?
|
| Pancreas | 1 | 2018 | 239 | 0.040 |
Why?
|
| Internationality | 1 | 2016 | 69 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2017 | 273 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2015 | 35 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 372 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 238 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 244 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2014 | 6 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 257 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 263 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 364 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 26582 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 425 | 0.030 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 4 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 560 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2013 | 35 | 0.030 |
Why?
|
| Brain | 1 | 2023 | 2216 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Lymphangioma | 1 | 2012 | 15 | 0.030 |
Why?
|
| Hemangioma, Capillary | 1 | 2012 | 7 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2012 | 20 | 0.030 |
Why?
|
| Hemangioma | 1 | 2012 | 60 | 0.030 |
Why?
|
| Microcirculation | 1 | 2012 | 106 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2012 | 41 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2014 | 217 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2012 | 66 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 146 | 0.030 |
Why?
|
| Bile Duct Diseases | 1 | 2012 | 22 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 1863 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 82 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1376 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 79 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1578 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 162 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 528 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 307 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 859 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 397 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 229 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 999 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5210 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3092 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 645 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 1538 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1577 | 0.020 |
Why?
|
| Pathology | 1 | 2007 | 30 | 0.020 |
Why?
|
| World Health Organization | 1 | 2007 | 103 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1186 | 0.020 |
Why?
|
| Urology | 1 | 2007 | 110 | 0.020 |
Why?
|
| United States | 1 | 2018 | 6672 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2007 | 572 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11352 | 0.010 |
Why?
|